TY - JOUR
T1 - Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice
T2 - Insights from the European multicenter GHOST-EU registry
AU - Ortega-Paz, Luis
AU - Capodanno, Davide
AU - Giacchi, Giuseppe
AU - Gori, Tommaso
AU - Nef, Holger
AU - Latib, Azeem
AU - Caramanno, Giuseppe
AU - Di Mario, Carlo
AU - Naber, Christoph
AU - Lesiak, Maciej
AU - Capranzano, Piera
AU - Wiebe, Jens
AU - Mehilli, Julinda
AU - Araszkiewicz, Aleksander
AU - Pyxaras, Stelios
AU - Mattesini, Alessio
AU - Geraci, Salvatore
AU - Naganuma, Toru
AU - Colombo, Antonio
AU - Münzel, Thomas
AU - Sabaté, Manel
AU - Tamburino, Corrado
AU - Brugaletta, Salvatore
N1 - Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2017/4
Y1 - 2017/4
N2 - Background: Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Results: A total of 320 (21.7%) patients were treated with overlapping BRS (overlap group), whereas the remaining 1,157 (78.3%) received no-overlap BRS (no-overlap group). The overlap group had significantly higher frequency of male sex, diabetes mellitus, stable angina, B2/C lesion type, SYNTAX score ≥22, lesion length >34 mm, use of intracoronary imaging guidance, pre- and postdilatation. At 1-year, there were no differences in PoCE between the overlap versus no-overlap group (18.4% vs. 18.2%; HR 1.07, [0.80–1.44]; P = 0.636), even after adjustment (HR 1.05, [0.48–2.20]; P = 0.904). Scaffold thrombosis rate did not differ either at one-month (1.3% vs. 1.5%, P = 0.769) or at 1-year (1.9% vs. 2.1%, P = 0.823). Conclusions: In “Real-world” clinical practice, overlapping BRS does not appear to have an impact on clinical outcomes as compared to no-overlapping BRS. These preliminary data should be confirmed.
AB - Background: Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Results: A total of 320 (21.7%) patients were treated with overlapping BRS (overlap group), whereas the remaining 1,157 (78.3%) received no-overlap BRS (no-overlap group). The overlap group had significantly higher frequency of male sex, diabetes mellitus, stable angina, B2/C lesion type, SYNTAX score ≥22, lesion length >34 mm, use of intracoronary imaging guidance, pre- and postdilatation. At 1-year, there were no differences in PoCE between the overlap versus no-overlap group (18.4% vs. 18.2%; HR 1.07, [0.80–1.44]; P = 0.636), even after adjustment (HR 1.05, [0.48–2.20]; P = 0.904). Scaffold thrombosis rate did not differ either at one-month (1.3% vs. 1.5%, P = 0.769) or at 1-year (1.9% vs. 2.1%, P = 0.823). Conclusions: In “Real-world” clinical practice, overlapping BRS does not appear to have an impact on clinical outcomes as compared to no-overlapping BRS. These preliminary data should be confirmed.
KW - bioresorbable scaffolds
KW - bioresorbable vascular scaffolds
KW - coronary artery disease
KW - percutaneous coronary intervention
UR - http://www.scopus.com/inward/record.url?scp=84994252933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994252933&partnerID=8YFLogxK
U2 - 10.1002/ccd.26674
DO - 10.1002/ccd.26674
M3 - Article
C2 - 27515568
AN - SCOPUS:84994252933
SN - 1522-1946
VL - 89
SP - 812
EP - 818
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
IS - 5
ER -